Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 12Other solid neoplasm 10Thoracic 9Head & Neck 6Gastrointestinal 6CNS 6Other hematologic neoplasm 5Genitourinary 4Breast 4Tumor-Agnostic 3Sarcoma 2Plasma cell 2Myeloid 2Lymphoid 2Dermatologic 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × adavosertib × Tumor-Agnostic × Clear all
NCT04197713 2026-04-29

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

National Cancer Institute (NCI)

Phase 1 Active not recruiting
13 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT02576444 2022-12-28

OLAPCO

Yale University

Phase 2 Terminated
67 enrolled 10 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡